Investor Presentaiton

35 IDE161 Clinical Development Strategy First-in-Class Opportunity for Patients with Breast, Ovarian & Other Solid Tumors with HRD IDE161 Phase 1/2 - Mono Clinical Development Plan and Combination Options IDE161 Monotherapy Dose Escalation and Expansion in HRD Tumors Dose Escalation Expansion Cohort: ER+, Her2-, HRD Breast Cancer Expansion Cohort: HRD Ovarian Cancer Expansion Cohort: HRD Tumors (Basket) Expansion Opportunities beyond HRD Tumors IDE161 Combinations - Preclinical Safety Profile Supports Multiple Opportunities ER+, Her2- Breast Cancer Patients with HRD Tumors → ~10% to 14% of Breast Cancer Ovarian Cancer Patients with HRD Tumors → ~50% of Ovarian Cancer Facile peripheral PD Biomarker for PARGI based on measurement of PAR in blood samples (PBMC's) 100- MSD PAR Assay Human PBMC Activity in PARPİ- and Dose Escalation IDE161+ Chemotherapy Other Potential Combinations Differentiated Sensitivity Improved Safety Profile Platinum-Resistant Settings relative to PARPI's Clinical Strategic Pillars IDEAYA Data PARG poly (ADP-ribose) glycohyrdolase; PAR = poly (ADP-ribose; PBMC = peripheral blood mononuclear cells relative to PARPI's Fold Change over Baseline 10- *** 0.001 0.004 0.01 IDE161 (uM) 0.04 0.12 0.37 1.11 3.33 IDEAVA BIOSCIENCES

View entire presentation